Literature DB >> 19448135

CYP2D6-CYP2C9 protein-protein interactions and isoform-selective effects on substrate binding and catalysis.

Murali Subramanian1, Michael Low, Charles W Locuson, Timothy S Tracy.   

Abstract

Cytochrome P450 (P450) protein-protein interactions have been observed with various in vitro systems. It is interesting to note that these interactions seem to be isoform-dependent, with some combinations producing no effect and others producing increased or decreased catalytic activity. With some exceptions, most of the work to date has involved P450s from rabbit, rat, and other animal species, with few studies including human P450s. In the studies presented herein, the interactions of two key drug-metabolizing enzymes, CYP2C9 and CYP2D6, were analyzed in a purified, reconstituted enzyme system for changes in both substrate-binding affinity and rates of catalysis. In addition, an extensive study was conducted as to the "order of mixing" for the reconstituted enzyme system and the impact on the observations. CYP2D6 coincubation inhibited CYP2C9-mediated (S)-flurbiprofen metabolism in a protein concentration-dependent manner. V(max) values were reduced by up to 50%, but no appreciable effect on K(m) was observed. Spectral binding studies revealed a 20-fold increase in the K(S) of CYP2C9 toward (S)-flurbiprofen in the presence of CYP2D6. CYP2C9 coincubation had no effect on CYP2D6-mediated dextromethorphan O-demethylation. The order of combination of the proteins (CYP2C9, CYP2D6, and cytochrome P450 reductase) influenced the magnitude of catalysis inhibition as well as the ability of increased cytochrome P450 reductase to attenuate the change in activity. A simple model, congruent with current results and those of others, is proposed to explain oligomer formation. In summary, CYP2C9-CYP2D6 interactions can alter catalytic activity and, thus, influence in vitro-in vivo correlation predictions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19448135      PMCID: PMC2712436          DOI: 10.1124/dmd.109.026500

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  27 in total

1.  Liver microsomal electron transport systems. Properties of a reconstituted, NADH-mediated benzo[a]pyrene hydroxylation system.

Authors:  S B West; A Y Lu
Journal:  Arch Biochem Biophys       Date:  1977-08       Impact factor: 4.013

2.  Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles.

Authors:  Timothy S Tracy; J Matthew Hutzler; Robert L Haining; Allan E Rettie; Matthew A Hummel; Leslie J Dickmann
Journal:  Drug Metab Dispos       Date:  2002-04       Impact factor: 3.922

3.  Evidence supporting the interaction of CYP2B4 and CYP1A2 in microsomal preparations.

Authors:  G F Cawley; S Zhang; R W Kelley; W L Backes
Journal:  Drug Metab Dispos       Date:  2001-12       Impact factor: 3.922

4.  Competitive interactions between cytochromes P450 2A6 and 2E1 for NADPH-cytochrome P450 oxidoreductase in the microsomal membranes produced by a baculovirus expression system.

Authors:  Y Tan; C J Patten; T Smith; C S Yang
Journal:  Arch Biochem Biophys       Date:  1997-06-01       Impact factor: 4.013

Review 5.  Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity.

Authors:  F P Guengerich
Journal:  Chem Res Toxicol       Date:  2001-06       Impact factor: 3.739

6.  Biochemical and genetic factors influencing drug metabolism. Influence of hepatic microsomal mixed function oxidation reactions on cellular metabolic control.

Authors:  R W Estabrook; M R Franklin; B Cohen; A Shigamatzu; A G Hildebrandt
Journal:  Metabolism       Date:  1971-02       Impact factor: 8.694

7.  Effects of conditions for reconstitution with cytochrome b5 on the formation of products in cytochrome P-450-catalyzed reactions.

Authors:  L D Gorsky; M J Coon
Journal:  Drug Metab Dispos       Date:  1986 Jan-Feb       Impact factor: 3.922

8.  Studies on the rate-determining factor in testosterone hydroxylation by rat liver microsomal cytochrome P-450: evidence against cytochrome P-450 isozyme:isozyme interactions.

Authors:  D R Dutton; S K McMillen; A J Sonderfan; P E Thomas; A Parkinson
Journal:  Arch Biochem Biophys       Date:  1987-06       Impact factor: 4.013

Review 9.  Organization of multiple cytochrome P450s with NADPH-cytochrome P450 reductase in membranes.

Authors:  Wayne L Backes; Rusty W Kelley
Journal:  Pharmacol Ther       Date:  2003-05       Impact factor: 12.310

10.  Cytochrome P-450 isozyme/isozyme functional interactions and NADPH-cytochrome P-450 reductase concentrations as factors in microsomal metabolism of warfarin.

Authors:  L S Kaminsky; F P Guengerich
Journal:  Eur J Biochem       Date:  1985-06-18
View more
  28 in total

1.  Effect of homomeric P450-P450 complexes on P450 function.

Authors:  James R Reed; J Patrick Connick; Dongmei Cheng; George F Cawley; Wayne L Backes
Journal:  Biochem J       Date:  2012-09-15       Impact factor: 3.857

2.  Single-molecule fluorescence spectroscopy using phospholipid bilayer nanodiscs.

Authors:  Abhinav Nath; Adam J Trexler; Peter Koo; Andrew D Miranker; William M Atkins; Elizabeth Rhoades
Journal:  Methods Enzymol       Date:  2010       Impact factor: 1.600

3.  Interactions among cytochromes P450 in microsomal membranes: oligomerization of cytochromes P450 3A4, 3A5, and 2E1 and its functional consequences.

Authors:  Dmitri R Davydov; Nadezhda Y Davydova; Elena V Sineva; James R Halpert
Journal:  J Biol Chem       Date:  2014-12-22       Impact factor: 5.157

4.  Identification of cytochrome P450 2C2 protein complexes in mouse liver.

Authors:  Bin Li; Peter Yau; Byron Kemper
Journal:  Proteomics       Date:  2011-08       Impact factor: 3.984

Review 5.  Correlating structure and function of drug-metabolizing enzymes: progress and ongoing challenges.

Authors:  Eric F Johnson; J Patrick Connick; James R Reed; Wayne L Backes; Manoj C Desai; Lianhong Xu; D Fernando Estrada; Jennifer S Laurence; Emily E Scott
Journal:  Drug Metab Dispos       Date:  2013-10-15       Impact factor: 3.922

6.  CYP2C9-CYP3A4 protein-protein interactions: role of the hydrophobic N terminus.

Authors:  Murali Subramanian; Harrison Tam; Helen Zheng; Timothy S Tracy
Journal:  Drug Metab Dispos       Date:  2010-03-09       Impact factor: 3.922

7.  Altered CYP2C9 activity following modulation of CYP3A4 levels in human hepatocytes: an example of protein-protein interactions.

Authors:  Diane Ramsden; Donald J Tweedie; Tom S Chan; Timothy S Tracy
Journal:  Drug Metab Dispos       Date:  2014-08-25       Impact factor: 3.922

8.  Development of an in vitro system with human liver microsomes for phenotyping of CYP2C9 genetic polymorphisms with a mechanism-based inactivator.

Authors:  Darcy R Flora; Timothy S Tracy
Journal:  Drug Metab Dispos       Date:  2011-12-28       Impact factor: 3.922

9.  Interactions between cytochromes P450 2B4 (CYP2B4) and 1A2 (CYP1A2) lead to alterations in toluene disposition and P450 uncoupling.

Authors:  James R Reed; George F Cawley; Wayne L Backes
Journal:  Biochemistry       Date:  2013-05-28       Impact factor: 3.162

10.  Interactions between CYP2E1 and CYP2B4: effects on affinity for NADPH-cytochrome P450 reductase and substrate metabolism.

Authors:  Cesar Kenaan; Erin V Shea; Hsia-lien Lin; Haoming Zhang; Matthew J Pratt-Hyatt; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2012-10-05       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.